A signal for skin tone
One short capsule trial found lower pigmentation readings at selected sites.
Site-specific benefit
Another oral trial found no significant overall pigmentation advantage. [1][2]
GSH & GSSG · ORAL AND TOPICAL EVIDENCE
Glutathione.
Skin tone.
Antioxidant science.
Small studies suggest a role in skin pigmentation, while separate research looks at glutathione stores in the body. The results depend on the route, the formula and what was measured.
Explore the findingsIngredient research, not proof of results for a finished Neurogan product.
01 / WHAT PEOPLE WANT TO KNOW
Skin tone and antioxidant support.
Two different questions.
A clearer lotion result
An oxidized-glutathione lotion reduced melanin readings compared with a control lotion.
Specific formula, specific result
This was GSSG, not a trial of a current L-glutathione cream or mist. [3]
Glutathione stores
Some oral studies found higher glutathione levels in blood and cells.
Biology, not a visible outcome
Another controlled trial was null. Higher blood levels do not prove better skin or health. [4][5]
Natural skin color is not a measure of health. Pigmentation readings measure skin melanin, not overall skin quality or a need to lighten your natural complexion.
02 / ORAL SKIN EVIDENCE
What did capsule studies find?
Oral GSH and oral GSSG were studied separately. Neither inherits the result of a topical lotion.
A short oral study found benefits at selected sites
Melanin readings fell more with glutathione at two of six measured sites. This was not a uniform whole-body effect. [1]
Read the methods, results and limits
- Who
- 60 healthy medical students in Bangkok; all completed. Two parallel groups.
- What & how long
- Oral glutathione capsules, 500 mg/day in two divided doses, for 4 weeks; placebo control.
- Measurements
- Melanin index at six sites; VISIA UV-spot measurements. ANCOVA adjusted for baseline values.
- Results
- Significant between-group reductions at the right face (p=0.021) and sun-exposed left forearm (p=0.036). Other sites did not meet statistical significance. The abstract also describes a similar UV-spot pattern.
- Limits
- Short follow-up, multiple sites and a narrow healthy population. Absolute baseline/endline readings and confidence intervals are not supplied in the accessible abstract, so no numerical efficacy chart is drawn.
- Safety & access
- Both groups were described as very well tolerated. Long-term safety was not established. Primary abstract verified; full text not retrieved.
A longer oral trial was mixed, not a clear pigmentation win
Overall melanin-index and UV-spot comparisons against placebo were not statistically significant. Selected wrinkle findings were favorable, but skin hydration was lower at some sites. [2]
Read the methods, results and limits
- Who
- 60 healthy women aged 20–50 in Bangkok enrolled; 57 analyzed: GSH 20, GSSG 18, placebo 19.
- What & how long
- 250 mg/day reduced glutathione (GSH, Setria) or oxidized glutathione (GSSG, AquaGluta), compared with placebo for 12 weeks. Visits at baseline and weeks 4, 8 and 12.
- Pigmentation
- No significant overall GSH or GSSG advantage for melanin index or UV spots. In the over-40 subgroup, GSH had a favorable right sun-exposed forearm result: 7 GSH participants versus 10 placebo participants, p=0.031. This exploratory site/subgroup result is not the overall trial result.
- Other results
- A wrinkle measure on the sun-protected left arm favored GSH (p=0.006). Elasticity and participant satisfaction did not differ significantly. Water content on the sun-protected left arm was lower with GSH than placebo (p=0.031), not a hydration benefit.
- Safety
- Two participants stopped after elevated liver-function tests; elevations were temporary. Itching, redness, small red spots and tiredness were reported. No serious adverse events were reported.
- Limits & access
- Primary full text, especially Results and Table 2, verified. Small groups, many outcomes/site comparisons and exploratory subgroups. Manufacturer supplied capsules and funded the work. The favorable abstract is less informative than the mixed primary results.
03 / TOPICAL SKIN EVIDENCE
A measurable lotion result.
Not a capsule result.
Lower melanin readings after 10 weeks
Mean melanin index, instrument units. Lower means less measured pigmentation, not a percentage improvement in skin health.
0150300
Mean2% GSSG lotion
Mean ± SD: 272.77 ± 26.17 at baseline; 243.47 ± 26.31 at week 10.
Placebo lotion
Mean ± SD: 274.13 ± 25.82 at baseline; 265.50 ± 25.81 at week 10.
The topical result belongs to an oxidized-glutathione lotion
The GSSG lotion lowered pigmentation readings. Some wrinkle and moisture measures improved, but elasticity did not differ from control. [3]
Read the methods, results and limits
- Who
- 30 healthy Filipino women aged 30–50, Fitzpatrick skin types III or IV; all completed. Each woman served as her own control.
- What & how long
- 2% weight/weight GSSG lotion versus placebo lotion, assigned to opposite sides of the face. About 0.5 g per designated side, twice daily for 10 weeks.
- Results
- Melanin-index means are shown above. Hydration favored GSSG at weeks 8 and 9, not consistently throughout the study. Wrinkle curvature favored GSSG at weeks 6 and 10; keratin index at weeks 6–10. Elasticity did not differ. Subjective skin-smoothing assessments also did not differ.
- Formula limits
- Table 1 shows differences in thickener/emulsifying-polymer amounts and potassium hydroxide as well as GSSG. It is a comparison of two lotions, not a perfectly identical vehicle with only the active changed. No direct reduced-GSH comparator was tested.
- Safety
- One woman had mild redness across the whole face early in the study, resolving without stopping. No reactions were attributed to GSSG. This small short study cannot establish long-term safety.
- Access & funding
- Primary full text and numerical Results verified. Manufacturer employees were among the authors. The study selected a narrow population and followed many outcomes; no lasting benefit after stopping was established.
04 / ORAL ANTIOXIDANT RESEARCH
Higher stores are not the same
as better health.
Longer supplementation raised body stores in one trial
A six-month trial found higher glutathione stores in several blood and cell compartments. It did not establish clearer skin, disease prevention or a clinical “detox” benefit. [4]
Read the methods, results and limits
- Who
- 54 healthy non-smoking adults.
- What & how long
- Oral GSH, 250 or 1,000 mg/day, compared with placebo for 6 months, with a 1-month washout.
- Results
- Blood GSH rose versus baseline during supplementation; the abstract reports dose- and time-related changes in several compartments. Levels returned to baseline after washout. Laboratory immune measures were secondary outcomes in a subset.
- Limits
- Biomarker outcomes are not clinical outcomes. The abstract does not give all group-level baseline/endline means or endpoint-specific denominators, so no quantitative benefit chart is shown.
- Access
- Primary abstract verified. Full text not retrieved for this review; the report is not a trial of Neurogan capsules.
A shorter controlled study found no biomarker benefit
Four weeks of oral glutathione did not significantly change oxidative-stress biomarkers or glutathione status versus placebo. [5]
Read the methods, results and limits
- Who
- 40 adults without acute or chronic disease; 39 completed per protocol.
- What & how long
- 500 mg GSH twice daily for 4 weeks, compared with placebo.
- Results
- No significant between-group changes in urinary F2-isoprostanes, urinary 8-OHdG, or glutathione indices. These are markers of oxidative stress and glutathione status, not skin-appearance outcomes.
- Limits
- Short duration and healthy population. This does not negate every longer-duration result, but it argues against assuming an inevitable biomarker benefit.
- Access
- Primary abstract verified. Available full-text XML retrieval failed, so this card is abstract-based.
Liposomal findings are a separate, preliminary story
Glutathione levels rose during a liposomal pilot. Without a placebo group, the study cannot establish the effect of supplementation as securely as a controlled trial. [6]
Read the methods, results and limits
- Who
- 12 healthy adults.
- What & how long
- Liposomal oral GSH, 500 or 1,000 mg/day for 4 weeks. Two active doses, not a placebo comparison.
- Results
- Higher glutathione concentrations and changes in laboratory oxidative-stress and immune markers were reported. No overall dose-group differences were detected, with limited power.
- Limits
- No visible skin endpoint. Liposomal delivery is not interchangeable with ordinary capsules, micellar preparations, topical GSH or topical GSSG. No product-specific absorption advantage follows from this pilot.
- Access
- Primary abstract and PubMed figure captions verified. Full-text XML retrieval failed; no absolute outcome chart is constructed from abstract maxima.
05 / FROM STUDY TO PRODUCT
The route and formula matter.
L-Glutathione Capsules 450mg
Oral: the record states 450 mg L-glutathione per capsule and 60 capsules per bottle. This is not the 250 or 500 mg/day skin-trial regimen, and the record does not establish liposomal delivery. Do not adjust a regimen to imitate a study without appropriate guidance.
L-Glutathione Face Cream 60ml 300mg
Topical: the title states 60 mL and 300 mg L-glutathione; the description lists a base of olive, rice bran, passion fruit and acai oils. The clinical chart used 2% w/w oxidized GSSG in a different lotion, not this reduced-L-glutathione cream. Container amount and volume do not establish a weight/weight match.
L-Glutathione Face Mist
Topical: the description states 120 mg L-glutathione with distilled water. The supplied description does not establish a per-spray glutathione dose. A water-based mist is not the studied GSSG lotion, and bottle milligrams do not show skin delivery or stability over use.
Product records checked September 10, 2026. Listed amounts are manufacturer descriptions, not independently verified potency or clinical equivalence. None of the studies summarized here tested these finished Neurogan products.
06 / SAFETY & PRACTICAL LIMITS
Keep expectations and use grounded.
For oral use
Short studies often reported good tolerability, but the oral skin trial also recorded temporary liver-enzyme elevations and mild symptoms. Ask a clinician before use if you take medicines, have liver or other medical conditions, are pregnant or breastfeeding, or are considering supplements for a child. [2]
Do not treat changes in blood glutathione as evidence that a supplement treats liver disease or removes toxins.
For skin use
Patch test a new cosmetic on a small area and stop if irritation develops. Keep facial products out of the eyes. Persistent or changing pigmentation deserves clinical assessment.
These studies do not replace sunscreen and do not establish safety or benefit for injected, intravenous or nasal glutathione. Combining oral and topical products has not been shown here to add benefit.
07 / REFERENCES
Read what each finding rests on.
Selected primary studies, not an exhaustive review. Source access is labeled. No finished Neurogan product trial was identified in these sources.
- PRIMARY ABSTRACT
Arjinpathana & Asawanonda · Oral glutathione and pigmentation (2010)
PMID 20524875 · DOI 10.3109/09546630903072947. Two significant sites among six; no verified numerical before/after means.
Read the primary source ↗ - PRIMARY FULL TEXT
Weschawalit et al. · Glutathione and its antiaging and antimelanogenic effects (2017)
PMID 28490897 · DOI 10.2147/CCID.S128339. Read Results and Table 2 for the overall null pigmentation findings.
Read the primary source ↗ - PRIMARY FULL TEXT
Watanabe et al. · Topical oxidized glutathione (2014)
PMID 25378941 · DOI 10.2147/CCID.S68424. Methods, Table 1 and Results/Figure 2 support the lotion comparison and chart.
Read the primary source ↗ - PRIMARY ABSTRACT
Richie et al. · Oral glutathione and body stores (2015)
PMID 24791752 · DOI 10.1007/s00394-014-0706-z. Six-month biomarker trial, not a skin trial.
Read the primary source ↗ - PRIMARY ABSTRACT
Allen & Bradley · Oral glutathione and oxidative stress (2011)
PMID 21875351 · DOI 10.1089/acm.2010.0716. Null four-week biomarker trial.
Read the primary source ↗ - PRIMARY ABSTRACT & FIGURE CAPTIONS
Sinha et al. · Liposomal glutathione pilot (2018)
PMID 28853742 · DOI 10.1038/ejcn.2017.132. Published online in 2017. Preliminary active-dose pilot, not an ordinary-capsule trial.
Read the primary source ↗